ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8⁺ T Cell Cytotoxicity

Figure 6

SP1 affected chemoresistance and immunotherapy. (a) Correlation analysis of SP1, BCL2L1, and PD-L1 in the GEPIA and TCIA databases. (b, c) The expression of BLC2L1 and PD-L1 in SGC7901 cells (b) and SGC7901/5-FU cells (c). (d) The apoptosis rate of SGC7901 cells with SP1 overexpression, ATXN2 silencing, and BCL2L1 silencing. (e) SGC7901 cells overexpressing SP1 were treated with an AKT inhibitor or nivolumab and cocultured with CD8⁺ T cells. The survival rate of SGC7901 cells was measured. (f) Schematic of the model for the SP1/ATXN2/PI3K-Akt/BCL2L1 and SP1/ATXN2/PI3K-Akt/PD-L1 pathways. The schematic was created with http://biorender.com. .

(a)

(b)

(c)

(d)

(e)

(f)